A syringe driver configured to automatically empty a mini-syringe extending along an injection axis and including a plunger configured to translate inside the mini-syringe, the driver includes a pushing element configured to cooperate with the plunger, a control unit configured to operate and control the pushing element in order to homogeneously empty the mini-syringe, an activable securing and detection system presenting: a securing system configured to receive and secure the mini-syringe, and a detection system configured to detect the presence and the correct positioning of the mini-syringe, configured to emit positive feedback when the mini-syringe is correctly secured. The control unit is configured to wait for positive feedback from the detection system for launching the operation of the pushing element.
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
2.
AZASETRON FOR THE PREVENTION OF HEARING LOSS IN SUBJECTS RECEIVING CISPLATIN
The present invention relates to azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention of hearing loss in a subject suffering from a cancer who is scheduled to receive a cumulative dose of cisplatin equal to or higher than about 300 mg/m2.
An isolated nucleic acid sequence including at least two copies of a miRNA target site of the miR183 family having a sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 21, or SEQ ID NO: 24, or a sequence having at least 90% identity with any one of SEQ ID NO: 1, SEQ ID NO: 21, or SEQ ID NO: 24. Also a vector including a regulatory element having at least one copy of this miRNA target site of the miR183 family. The isolated nucleic acid sequence and the vector may be particularly useful for controlling the expression of a gene of interest, for example when designing and developing gene therapies.
Azasetron or an analog thereof, or a pharmaceutically acceptable salt and/or solvate thereof, for treating severe or profound sudden sensorineural hearing loss (SSNHL) in a subject in need thereof. In particular, azasetron or an analog thereof, or a pharmaceutically acceptable salt and/or solvate thereof, for treating severe or profound SSNHL in a subject suffering from severe or profound SSNHL associated with (i) a hearing threshold at baseline corresponding to a pure tone audiometry (PTA) at baseline equal to or greater than 70 dB, preferably equal to or greater than 80 dB, more preferably equal to or greater than 90 dB; (ii) a hearing loss at baseline equal to or greater than 91 dB corresponding to a profound hearing loss according to the American Speech-Language-Hearing Association (ASHA) classification; (iii) a hearing loss at baseline affecting frequencies equal to or lower than 2000 Hz; and/or (iv) the presence of vertigo at baseline.
A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
The present invention relates to azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the preservation of residual hearing following cochlear implantation in a subject in need thereof, wherein the subject has a hearing threshold at baseline in at least one ear corresponding to an unaided audiometric threshold at baseline greater than 65 dB, the unaided audiometric threshold being expressed as the average of at least 3 values each determined at a different frequency within the range from 0.25 kHz to 0.75 kHz.
The present invention relates to a recombinant adeno-associated virus (rAAV) vector encoding connexin 26 (CX26). The present invention further relates to the use of said AAV vector in the treatment of genetic hearing loss.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
The present invention relates to an isolated nucleic acid sequence comprising at least two copies of a miRNA target site of the miR183 family having a sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 21, or SEQ ID NO: 24, or a sequence having at least 90% identity with any one of SEQ ID NO: 1, SEQ ID NO: 21, or SEQ ID NO: 24. The present invention also relates to a vector comprising a regulatory element comprising at least one copy of said miRNA target site of the miR183 family. The isolated nucleic acid sequence and the vector may be particularly useful for controlling the expression of a gene of interest, for example when designing and developing gene therapies.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present invention relates to azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment of severe or profound sudden sensorineural hearing loss (SSNHL) in a subject in need thereof. In particular, the present invention relates to azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment of severe or profound SSNHL in a subject suffering from severe or profound SSNHL associated with (i) a hearing threshold at baseline corresponding to a pure tone audiometry (PTA) at baseline equal to or greater than 70 dB, preferably equal to or greater than 80 dB, more preferably equal to or greater than 90 dB; (ii) a hearing loss at baseline equal to or greater than 91 dB corresponding to a profound hearing loss according to the American Speech-Language- Hearing Association (ASHA) classification; (iii) a hearing loss at baseline affecting frequencies equal to or lower than 2000 Hz; and/or (iv) the presence of vertigo at baseline.
A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
The present invention relates to azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment of severe or profound sudden sensorineural hearing loss (SSNHL) in a subject in need thereof. In particular, the present invention relates to azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment of severe or profound SSNHL in a subject suffering from severe or profound SSNHL associated with (i) a hearing threshold at baseline corresponding to a pure tone audiometry (PTA) at baseline equal to or greater than 70 dB, preferably equal to or greater than 80 dB, more preferably equal to or greater than 90 dB; (ii) a hearing loss at baseline equal to or greater than 91 dB corresponding to a profound hearing loss according to the American Speech-Language- Hearing Association (ASHA) classification; (iii) a hearing loss at baseline affecting frequencies equal to or lower than 2000 Hz; and/or (iv) the presence of vertigo at baseline.
A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
Disclosed is a method for treating ear disorders, including the administration of (+)-azasetron, or a pharmaceutically acceptable salt and/or solvate thereof.
The therapeutic use of azasetron or an analogue thereof for treating and/or preventing a lesion in the central auditory nervous system (CANS) in an individual. The treatment of lesions in the CANS with azasetron also prevents, inhibits, and/or reduces the loss of the central auditory neuron cells in the brainstem.
The present invention relates to the therapeutic use of azasetron or an analogue thereof for treating and/or preventing a lesion in the central auditory nervous system (CANS). The inventors show that treatment of lesions in the CANS with azasetron allows reducing the loss of neurons in the brainstem.
terttert-butyl azetidin- 3-yl(methyl)carbamate, or another N-protected N-methylazetidin-3-amine, and performing the following steps: (a) coupling reaction of both compounds in dimethyl sulfoxide in presence of potassium carbonate to afford an intermediate protected compound; and (b) deprotection of the protected compound to afford 2-isobutyl-6-(3-(methylamino)azetidin-1-yl)pyrimidin-4-amine. The invention also relates to a process for manufacturing the intermediate protected compound, wherein deprotection step (b) is omitted. The invention also relates to the compounds obtained from the processes according to the invention.
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
20.
(+)-azasetron for use in the treatment of ear disorders
Disclosed is a method for treating ear disorders, including the administration of (+)-azasetron, or a pharmaceutically acceptable salt and/or solvate thereof.
The present invention relates to a compound for use for preventing ototoxicity in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition or a medicament comprising the compound of the invention.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical products for use in science, bases (chemical
products), chemical products used for the manufacture of
pharmaceutical products. Pharmaceutical and veterinary products for the treatment
and/or prevention of diseases of the ears, tablets for
pharmaceutical use; medicines for human and veterinary use;
chemical and biological preparations for medical or
pharmaceutical use, preparations of microorganisms for
medical use; capsules for medicines. Academic and clinical research services in the scientific,
biological, medical and technological fields provided by
engineers and scientists, chemical analysis, clinical
studies; computer system design, these services provided in
the field of medical research relating to vestibular
disorders.
27.
Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Chemicals for use in science used in the manufacture of pharmaceuticals and prevention's medicines for pathologies of the inner ear, Bases, namely chemical preparations used for the manufacture of pharmaceuticals and prevention's medicines for pathologies of the inner ear, Chemical products for use in the manufacture of pharmaceuticals, namely additives for use in the manufacture of pharmaceuticals, chemicals for use in the pharmaceutical industry.
(2) Pharmaceutical and veterinary preparations for the treatment and prevention of diseases of the ears, Capsules for pharmaceutical purposes for the treatment and prevention of pathologies of the inner ear; Medicines for human or veterinary purposes for the treatment and prevention of pathologies of the inner ear; Chemical and biological preparations for medical and pharmaceutical purposes for the treatment and prevention of pathologies of the inner ear, Micro-organism cultures for medical use; Capsules for medicines for the treatment and prevention of pathologies of the inner ear. (1) Clinical and academic research in the fields of science, biology, medicine and technology provided by engineers and scientists in the field of medical research relating to inner ear disorders, Chemical analysis, Clinical research in the field of medical research relating to inner ear disorders; Design of computer systems, The aforesaid services being provided in the field of medical research relating to vestibular disorders.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical preparations for use in science; chemical preparations in the nature of bases for use in science; chemical preparations used for the manufacture of pharmaceutical products Pharmaceutical and veterinary products for the treatment and/or prevention of diseases of the ears; tablets for pharmaceutical use for the treatment of pathologies of the inner ear; medicines for human and veterinary use for the treatment of pathologies of the inner ear; chemical and biological preparations for medical or pharmaceutical use for the treatment of pathologies of the inner ear; preparations of microorganisms for medical use for the treatment of pathologies of the inner ear; capsules for use as medicines, for the treatment of pathologies of the inner ear Academic and clinical research services in the scientific, biological, medical and biotechnological fields related to inner ear disorders and provided by engineers and scientists; chemical analysis; clinical studies, namely, conducting scientific feasibility studies, preclinical studies and clinical trials; computer system design related to the medical field and the pathologies of the inner ear; all of the foregoing services provided in the field of medical research relating to vestibular disorders
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
The present invention relates to a compound that impairs or prevents accumulation of platinum drugs within vestibular hair cells and/or vestibular primary neurons for use in treating platinum drugs induced vestibulotoxicity.
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/277 - NitrilesIsonitriles ayant un cycle, p. ex. vérapamil
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
A61K 31/4168 - 1,3-Diazoles ayant un atome d'azote lié en position 2, p. ex. clonidine
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
32.
CALCINEURIN INHIBITORS FOR USE IN THE TREATMENT OF LESIONAL VESTIBULAR DISORDERS
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals for use in science, Bases (chemical preparations), Chemical products for use in the manufacture of pharmaceutical preparations. Pharmaceutical and veterinary preparations for the treatment and/or prevention of diseases of the ears, Capsules for pharmaceutical purposes; Medicines for human or veterinary purposes; Chemical and biological preparations for medical and pharmaceutical purposes, Micro-organism cultures for medical use; Capsules for medicines. Clinical and academic research in the fields of science, biology, medicine and technology provided by engineers and scientists, Chemical analysis, Clinical research; Design of computer systems, The aforesaid services being provided in the field of medical research relating to vestibular disorders.
